Invention Grant
- Patent Title: Ethyldiamine orexin receptor antagonists
-
Application No.: US15532602Application Date: 2015-12-14
-
Publication No.: US10011595B2Publication Date: 2018-07-03
- Inventor: Ronald M. Kim , Scott D. Kuduk , Nigel Liverton , Gang Zhou
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent J. Eric Thies; John C. Todaro
- International Application: PCT/US2015/065454 WO 20151214
- International Announcement: WO2016/100161 WO 20160623
- Main IPC: C07D213/84
- IPC: C07D213/84 ; C07D239/42 ; C07D401/12 ; C07D401/14 ; C07D403/12 ; C07D403/14 ; C07D405/12 ; C07D413/12 ; A61K31/44 ; A61K31/4439 ; A61K31/506
Abstract:
The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Public/Granted literature
- US20170355692A1 ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS Public/Granted day:2017-12-14
Information query
IPC分类:
